Trending: Halozyme Drops Bid for Evotec

Dow Jones11-23

1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)

 

(END) Dow Jones Newswires

November 22, 2024 13:50 ET (18:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment